Vigil Neuroscience to Present at Upcoming Investor Conferences
Vigil Neuroscience, Inc. (Nasdaq: VIGL) is a clinical-stage biotechnology company dedicated to leveraging microglia for treating neurodegenerative diseases. Today, the company announced that its management team will be presenting at two upcoming investor conferences.
Details of Upcoming Conferences
Morgan Stanley 22nd Annual Global Healthcare Conference
Format: Fireside Chat
Date/Time: Thursday, September 5th at 2:35 p.m. ET
H.C. Wainwright 26th Annual Global Investment Conference
Format: Fireside Chat
Date/Time: Tuesday, September 10th at 10:30 a.m. ET
Availability of Webcasts
Live webcasts of these events will be accessible on the Company’s website in the “Events & Presentations” section of the “Investors” page. Archived versions will be available for about 90 days after the presentations, providing stakeholders the opportunity to catch up on any information they may have missed.
About Vigil Neuroscience
Vigil Neuroscience is a clinical-stage biotechnology firm that aims to develop treatments for both rare and common neurodegenerative diseases by enhancing the function of microglia, the brain's immune cells. The company employs cutting-edge neuroscience tools and methodologies across various therapeutic approaches to create precision therapies designed to improve patient outcomes.
One of Vigil’s primary clinical candidates is Iluzanebart, a fully human monoclonal antibody agonist that targets the triggering receptor expressed on myeloid cells 2 (TREM2). This candidate specifically addresses adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and severe neurodegenerative disorder. In addition to Iluzanebart, Vigil is also developing VG-3927, a novel small molecule TREM2 agonist intended for treating common neurodegenerative diseases associated with microglial dysfunction, with a particular focus on Alzheimer’s disease (AD) patients, including those with TREM2 and other related variants.
Investor Outreach and Communication
Vigil Neuroscience is committed to transparency with its investors and regularly updates the “Investors” section of its website. The company encourages both current and prospective investors to visit www.vigilneuro.com frequently for the latest news and important information about the company.
Investor Contact
Leah Gibson
Vice President, Investor Relations & Corporate Communications
Vigil Neuroscience, Inc.
lgibson@vigilneuro.com
Media Contact
Megan McGrath
CTD Comms, LLC
megan@ctdcomms.com
Frequently Asked Questions
What is the focus of Vigil Neuroscience?
Vigil Neuroscience is dedicated to developing innovative treatments for neurodegenerative diseases by utilizing the role of microglia in maintaining brain health.
What are the key products in Vigil's pipeline?
The key products include Iluzanebart, which is aimed at treating ALSP, and VG-3927, a drug targeting Alzheimer's disease and other conditions linked to microglial dysfunction.
When are the investor conferences that Vigil will attend?
Vigil will present at the Morgan Stanley Global Healthcare Conference on September 5th and the H.C. Wainwright Investment Conference on September 10th.
Where can investors access the live presentations?
Investors can find the live webcasts of the presentations on Vigil's website in the “Events & Presentations” section.
Who should investors contact for more information?
Investors can contact Leah Gibson, the Vice President of Investor Relations, for any questions regarding the company's strategy and presentations.
